Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Bayer Pharma AG | 778 |
| 2 | Bayer AG | 327 |
| 3 | Bayer Intellectual Property GmbH | 136 |
| 4 | German Cancer Research Center | 130 |
| 5 | Dana Farber Cancer Institute Inc | 65 |
| 6 | Ferring BV | 50 |
| 7 | Case Western Reserve University | 36 |
| 8 | Harvard University | 33 |
| 9 | General Hospital Corp | 23 |
| 10 | Ceva Sante Animale SA | 21 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 1,693 |
| 2 | A61P | Therapeutic activity (drug indications) | 1,684 |
| 3 | C07D | Heterocyclic compounds | 1,016 |
| 4 | C07K | Peptides | 126 |
| 5 | C07C | Acyclic and carbocyclic compounds | 86 |
| 6 | C07F | Organometallic compounds | 76 |
| 7 | Y02A | Climate change adaptation | 73 |
| 8 | G01N | Investigating / analysing materials | 72 |
| 9 | C07B | General methods of organic chemistry | 66 |
| 10 | C12Q | Measuring/testing involving enzymes | 64 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| DRUG-DEVICE UNIT CONTAINING QUINAGOLIDE | 2016 | Ferring BV | 4 |
| DRUG-DEVICE UNIT CONTAINING QUINAGOLIDE | 2017 | FERRING B. V. | 2 |
| STEREOSELECTIVE SYNTHESIS OF INTERMEDIATES AND SYNTHESIS OF QUINAGOLIDS | 2024 | Ferring BV | 0 |
| Pharmaceutical device unit containing quinagolide | 2023 | Ferring BV | 0 |
| Drug-device unit containing quinagolide | 2016 | Ferring BV | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Pituitary Gland Disorders and Treatments | 4 |
| 2 | Adrenal and Paraganglionic Tumors | 1 |
| 3 | Growth Hormone and Insulin-like Growth Factors | 1 |
| 4 | Hormonal and reproductive studies | 1 |
| 5 | TGF-β signaling in diseases | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Annamaria Colao | Federico II University Hospital | 19 |
| 2 | Judith Brownell | Radboud University Nijmegen | 18 |
| 3 | Gaetano Lombardi | Federico II University Hospital | 16 |
| 4 | Antonella Di Sarno | Federico II University Hospital | 11 |
| 5 | P. Lacasse | Agriculture and Agri-Food Canada | 11 |
| 6 | Carolina Di Somma | Federico II University Hospital | 9 |
| 7 | Diego Ferone | Federico II University Hospital | 9 |
| 8 | Bartolomeo Merola | Federico II University Hospital | 8 |
| 9 | Francesca Sarnacchiaro | Federico II University Hospital | 8 |
| 10 | Rosario Pivonello | University of Naples Federico II | 7 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Autoradiographic localization of dopamine D1 and D2 receptors in the brain of several mammalian species | 1990 | 212 | Neurotransmitter Receptor Influence on Behavior |
| Prolactinomas in Children and Adolescents. Clinical Presentation and Long-Term Follow-Up | 1998 | 176 | Glioma Diagnosis and Treatment |
| Dopamine D2 receptors in the rat brain: autoradiographic visualization using a high-affinity selective agonist ligand | 1987 | 157 | Neurotransmitter Receptor Influence on Behavior |
| Effect of Different Dopaminergic Agents in the Treatment of Acromegaly | 1997 | 151 | Pituitary Gland Disorders and Treatments |
| Correlation of in Vitro and in Vivo Somatotropic Adenoma Responsiveness to Somatostatin Analogs and Dopamine Agonists with Immunohistochemical Evaluation of Somatostatin and Dopamine Receptors and Electron Microscopy | 2008 | 125 | Growth Hormone and Insulin-like Growth Factors |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Quinagolide?
Which organizations hold the most patents related to Quinagolide?
What are the primary research topics associated with Quinagolide studies?
Who are the most prolific authors publishing research on Quinagolide?
What is the recent patent activity trend for Quinagolide?